CA2683056C - Reprogramming of somatic cells - Google Patents

Reprogramming of somatic cells Download PDF

Info

Publication number
CA2683056C
CA2683056C CA2683056A CA2683056A CA2683056C CA 2683056 C CA2683056 C CA 2683056C CA 2683056 A CA2683056 A CA 2683056A CA 2683056 A CA2683056 A CA 2683056A CA 2683056 C CA2683056 C CA 2683056C
Authority
CA
Canada
Prior art keywords
cells
cell
somatic
reprogramming
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2683056A
Other languages
English (en)
French (fr)
Other versions
CA2683056A1 (en
Inventor
Rudolf Jaenisch
Jacob Hanna
Marius Wernig
Christopher J. Lengner
Alexander Meissner
Oliver Tobias Brambrink
G. Grant Welstead
Ruth Foreman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Whitehead Institute for Biomedical Research
Original Assignee
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute for Biomedical Research filed Critical Whitehead Institute for Biomedical Research
Priority to CA3071055A priority Critical patent/CA3071055A1/en
Publication of CA2683056A1 publication Critical patent/CA2683056A1/en
Application granted granted Critical
Publication of CA2683056C publication Critical patent/CA2683056C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0273—Cloned vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8775—Murine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91005—Transferases (2.) transferring one-carbon groups (2.1)
    • G01N2333/91011—Methyltransferases (general) (2.1.1.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Environmental Sciences (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
CA2683056A 2007-04-07 2008-04-07 Reprogramming of somatic cells Active CA2683056C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3071055A CA3071055A1 (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US92212107P 2007-04-07 2007-04-07
US60/922,121 2007-04-07
US95934107P 2007-07-12 2007-07-12
US60/959,341 2007-07-12
US3606508P 2008-03-12 2008-03-12
US61/036,065 2008-03-12
PCT/US2008/004516 WO2008124133A1 (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3071055A Division CA3071055A1 (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Publications (2)

Publication Number Publication Date
CA2683056A1 CA2683056A1 (en) 2008-10-16
CA2683056C true CA2683056C (en) 2020-03-24

Family

ID=39831277

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3071055A Pending CA3071055A1 (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells
CA2683056A Active CA2683056C (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3071055A Pending CA3071055A1 (en) 2007-04-07 2008-04-07 Reprogramming of somatic cells

Country Status (9)

Country Link
US (5) US9382515B2 (enExample)
EP (3) EP3878949B1 (enExample)
JP (8) JP2010523117A (enExample)
CN (2) CN105861443A (enExample)
AU (1) AU2008236629B2 (enExample)
CA (2) CA3071055A1 (enExample)
MX (2) MX352541B (enExample)
RU (1) RU2502799C2 (enExample)
WO (1) WO2008124133A1 (enExample)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
US20070044164A1 (en) 2005-05-31 2007-02-22 Cold Spring Harbor Laboratory Methods for producing microRNAs
WO2007016566A2 (en) 2005-08-01 2007-02-08 Nupotential, Llc Production of reprogrammed cells with restored potential
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
KR101420740B1 (ko) 2005-12-13 2014-07-17 교또 다이가꾸 핵초기화 인자
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
CN105861443A (zh) 2007-04-07 2016-08-17 怀特黑德生物医学研究所 体细胞重编程
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
EP3078738B1 (en) 2007-08-31 2020-05-20 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
WO2009067757A1 (en) * 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving oct4 protein
EP2227241A1 (en) * 2007-11-30 2010-09-15 Cytomatrix PTY LTD Methods of inducing pluripotency involving sox2 protein
KR101532442B1 (ko) 2007-12-10 2015-06-29 고쿠리츠 다이가쿠 호진 교토 다이가쿠 효율적인 핵 초기화 방법
JP5626619B2 (ja) * 2008-12-08 2014-11-19 国立大学法人京都大学 効率的な核初期化方法
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
AU2009234423A1 (en) * 2008-04-07 2009-10-15 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through RNA interference
ES2722198T3 (es) 2008-05-02 2019-08-08 Univ Kyoto Método de reprogramación nuclear
CN105671065A (zh) * 2008-06-13 2016-06-15 怀特黑德生物医学研究所 细胞编程和重编程
WO2010004989A1 (ja) 2008-07-07 2010-01-14 タカラバイオ株式会社 多能性幹細胞の製造方法
US20110231944A1 (en) * 2008-09-04 2011-09-22 Riken B cell-derived ips cells and application thereof
US20100062534A1 (en) * 2008-09-09 2010-03-11 The General Hospital Corporation Inducible lentiviral vectors for reprogramming somatic cells
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
JP5764497B2 (ja) 2008-12-23 2015-08-19 サジティス・インコーポレイテッド ケタールアミド化合物、作成方法、および適用
KR101764100B1 (ko) * 2009-02-27 2017-08-02 고쿠리츠 다이가쿠 호진 교토 다이가쿠 신규한 핵 재프로그래밍 물질
EP2408904B1 (en) * 2009-03-20 2017-10-18 Mesoblast, Inc. Production of reprogrammed pluripotent cells
CN101580816B (zh) * 2009-04-23 2012-02-29 中国科学院广州生物医药与健康研究院 诱导多能性干细胞快速高效产生的新型无血清培养基以及使用其的方法
US20110088107A1 (en) * 2009-04-24 2011-04-14 Yaqub Hanna Compositions and methods for deriving or culturing pluripotent cells
EP2451982B1 (en) 2009-07-09 2014-11-12 Whitehead Institute For Biomedical Research Compositions and methods for mammalian genetics and uses thereof
JP5709015B2 (ja) 2009-08-19 2015-04-30 国立大学法人大阪大学 角膜移植用シート
US8420352B2 (en) 2009-08-27 2013-04-16 Synaptic Research, Llc Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells
WO2011050470A1 (en) * 2009-10-29 2011-05-05 Mcmaster University Generating induced pluripotent stem cells and progenitor cells from fibroblasts
US9696297B2 (en) * 2009-12-23 2017-07-04 Salk Institute For Biological Studies Method for preparing an X chromosome inactivated female human neural cell
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
JP2013545439A (ja) 2010-09-17 2013-12-26 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 多能性幹細胞の有用性および安全性の特徴決定を行うための機能的ゲノミクスアッセイ
EP2635678A4 (en) 2010-11-04 2014-04-23 Univ Kyoto METHOD FOR EFFICIENT MANUFACTURE OF INDUCED PLURIPOTENTER STEM CELLS
EP2647699B1 (en) 2010-12-03 2020-04-01 Kyoto University Efficient method for establishing induced pluripotent stem cells
WO2012115270A1 (ja) * 2011-02-25 2012-08-30 学校法人慶應義塾 ｉＰＳ細胞クローンの選択方法、及びその選択方法に用いる遺伝子の選択方法
CN102731653B (zh) * 2011-04-06 2013-12-11 李凌松 一种抗磷酸化Oct4蛋白的抗体及其应用
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
DK3260140T3 (da) 2011-12-05 2021-04-19 Factor Bioscience Inc Fremgangsmåder og produkter til transficering af celler
CN104781396A (zh) * 2012-01-17 2015-07-15 小利兰·斯坦福大学托管委员会 用于体细胞核重编程的先天免疫激活
WO2013163296A1 (en) * 2012-04-24 2013-10-31 The Brigham And Women's Hospital, Inc. Generating pluripotent cells de novo
EP2861238A4 (en) 2012-06-05 2016-03-16 Capricor Inc OPTIMIZED METHODS FOR GENERATING CARDIAC STEM CELLS FROM CARDIAC TISSUE AND THEIR USE IN CARDIAC THERAPY
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US20150267174A1 (en) 2012-10-09 2015-09-24 Nakanobu Hayashi Reprogramming peptide and use thereof
US20140287932A1 (en) 2012-10-25 2014-09-25 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
BR122019025681B1 (pt) 2012-11-01 2023-04-18 Factor Bioscience Inc Método para inserir uma sequência de ácido nucleico em uma localização segura de um genoma de uma célula
CA2895791A1 (en) 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
AU2014249148B2 (en) * 2013-03-11 2020-04-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
HK1220232A1 (zh) 2013-03-15 2017-04-28 怀特黑德生物医学研究院 用於神经变性疾病的细胞性发现平台
JP2016521971A (ja) 2013-04-23 2016-07-28 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 単離ナイーブ型多能性幹細胞およびそれを発生させる方法関連出願本出願は、米国特許法１１９条第（ｅ）項に基づき、２０１４年１月２９日出願の米国特許仮出願第６１／９３２，９３５号、２０１３年９月１７日出願の米国特許仮出願第６１／８７８，７６９号、および２０１３年４月２３日出願の米国特許仮出願第６１／８１４，９２０号の優先権を主張する。また、本出願は、同時に提出された同出願人による同時係属出願である、ＹａｑｕｂＨＡＮＮＡ、ＮｏａＮＯＶＥＲＳＨＴＥＲＮ、およびＹｏａｃｈＲＡＩＳによる米国特許出願（発明の名称「単離ナイーブ型多能性幹細胞およびそれを発生させる方法（ＩＳＯＬＡＴＥＤＮＡＩＶＥＰＬＵＲＩＰＯＴＥＮＴＳＴＥＭＣＥＬＬＳＡＮＤＭＥＴＨＯＤＳＯＦＧＥＮＥＲＡＴＩＮＧＳＡＭＥ）」）（代理人事件記録簿第５８８７０号）にも関する。上記出願の内容はその全体を参考として本明細書に組み込む。
CA2912172A1 (en) 2013-06-05 2014-12-11 Bellicum Pharmaceuticals, Inc. Methods for inducing partial apoptosis using caspase polypeptides
JP6697380B2 (ja) 2013-06-10 2020-05-20 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 多能性幹細胞の有用性および安全性を特徴付けるための初期発生ゲノムアッセイ
US20160222347A1 (en) 2013-09-12 2016-08-04 Kaneka Corporation Method for inducing differentiation of induced pluripotent stem cells and method for selecting the same
WO2015069736A1 (en) 2013-11-08 2015-05-14 The Mclean Hospital Corporation METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS
WO2015117021A1 (en) 2014-01-31 2015-08-06 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
EP3991751A1 (en) 2014-02-10 2022-05-04 The Board of Trustees of the Leland Stanford Junior University Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mrna
RU2711942C2 (ru) 2014-03-19 2020-01-23 Виселл Терапеутикс, Инк. Способы, относящиеся к плюрипотентным клеткам
EP3194572B1 (en) 2014-07-30 2023-10-25 Yeda Research and Development Co. Ltd. Media for culturing pluripotent stem cells
US11261453B2 (en) 2014-09-12 2022-03-01 Whitehead Institute For Biomedical Research Cells expressing apolipoprotein E and uses thereof
US11357799B2 (en) 2014-10-03 2022-06-14 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
JP2018504122A (ja) 2015-01-26 2018-02-15 フェイト セラピューティクス，インコーポレイテッド 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
EP3543339A1 (en) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10961532B2 (en) * 2015-04-07 2021-03-30 The General Hospital Corporation Methods for reactivating genes on the inactive X chromosome
CA3019311A1 (en) 2015-04-15 2016-10-20 University Of Massachusetts Compositions and methods for xi chromosome reactivation
US20170044609A1 (en) * 2015-04-24 2017-02-16 California Institute Of Technology Reactivation of x chromosome genes
EP3286310A4 (en) 2015-04-24 2019-01-09 California Institute of Technology REACTIVATION OF X-CHROMOSOME GENES
BR112018001232A2 (pt) 2015-07-21 2018-09-25 The Children's Medical Center Corporation pd-l1 que expressa células-tronco hematopoéticas e usos
US10662409B2 (en) * 2015-09-09 2020-05-26 Trustees Of Tufts College Methods of generating neural stem cells
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CN105624117A (zh) * 2016-01-18 2016-06-01 哈尔滨医科大学 一种低氧促进小鼠成纤维细胞重编程为心肌细胞的方法
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
WO2017223199A1 (en) * 2016-06-22 2017-12-28 Xcell Biosciences, Inc. Methods for increasing cell culture transfection efficiency and cellular reprogramming
CN109803977B (zh) 2016-08-17 2023-03-17 菲克特生物科学股份有限公司 核酸产品及其施用方法
WO2018035495A1 (en) 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
CN106544315A (zh) * 2016-10-12 2017-03-29 广东艾时代生物科技有限责任公司 一种脂肪间充质干细胞诱导成多能干细胞的方法
JP2019537427A (ja) 2016-10-27 2019-12-26 カリフォルニア インスティチュート オブ テクノロジー Ｘ染色体の再活性化のためのｈｄａｃ阻害剤組成物
CN110402284B (zh) 2016-12-16 2024-03-08 伊维瓦医疗有限公司 用于基底膜支架的薄膜插入
FI3565891T3 (fi) 2017-01-09 2023-07-04 Whitehead Inst Biomedical Res Menetelmiä geeniekspression muuttamiseksi häiritsemällä säätelysilmukoita muodostavia transkriptiotekijämultimeerejä
WO2018159805A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 膵前駆細胞の製造方法
JP7303743B2 (ja) * 2017-04-05 2023-07-05 アスガード セラピューティクス エービー 細胞を樹状細胞または抗原提示細胞にリプログラムするための組成物、その方法および使用
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
JPWO2018230588A1 (ja) 2017-06-14 2020-04-16 武田薬品工業株式会社 細胞封入デバイス
WO2019060708A1 (en) 2017-09-22 2019-03-28 The Children's Medical Center Corporation TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS
PL241125B1 (pl) 2017-11-30 2022-08-08 Gdanski Univ Medyczny Kompozycja farmaceutyczna do zastosowania jako środek do pobudzania regeneracji lub gojenia ran
BR112020010539A2 (pt) 2017-11-30 2020-11-17 Kyoto University métodos para produção e para proliferação de células da crista neural, para produção de células nervosas, células da glia, células estromais mesenquimais, células ósseas, condrócitos, células da córnea ou células pigmentares e para cultivar células da crista neural, meio, estoque congelado, e, uso de um meio
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
JP7267607B2 (ja) 2017-12-22 2023-05-02 オリヅルセラピューティクス株式会社 細胞培養装置、培養液アスピレータ及び細胞培養方法
CN108624621B (zh) * 2018-01-17 2019-04-12 中国科学院上海生命科学研究院 非人灵长类的体细胞克隆动物的制备方法
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
US20210060210A1 (en) 2018-03-19 2021-03-04 Kyoto University Hydrogel capsule
US11401264B2 (en) 2018-03-30 2022-08-02 Orizuru Therapeutics, Inc. Heterocyclic compound
WO2019189545A1 (ja) 2018-03-30 2019-10-03 国立大学法人京都大学 細胞の製造方法
WO2019189554A1 (ja) 2018-03-30 2019-10-03 国立大学法人京都大学 心筋細胞成熟促進剤
CN112313327B (zh) 2018-04-23 2024-04-19 千纸鹤治疗公司 增殖抑制剂
CN112912490B (zh) 2018-08-03 2023-12-26 千纸鹤治疗公司 细胞制造方法
DK3835415T3 (en) 2018-08-10 2025-01-02 Univ Kyoto Fremgangsmåde til fremstilling af cd3-positiv celle
CN112639111B (zh) 2018-08-10 2023-07-21 国立大学法人京都大学 使用阳离子性脂质的转染心肌细胞的方法
KR20210049779A (ko) 2018-08-22 2021-05-06 고쿠리츠 다이가쿠 호진 교토 다이가쿠 장관 신경전구세포의 제조 방법
WO2020045610A1 (ja) 2018-08-31 2020-03-05 ノイルイミューン・バイオテック株式会社 Ｃａｒ発現ｔ細胞及びｃａｒ発現ベクター
KR102892433B1 (ko) 2018-09-19 2025-11-27 오리즈루 세라퓨틱스 가부시키가이샤 인슐린 산생 세포
AU2019342197B2 (en) 2018-09-21 2025-10-16 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching mRNA coding for secreted proteins
EP3868869A4 (en) 2018-10-15 2022-08-03 Public University Corporation Yokohama City University Nutrition composition
TW202039543A (zh) 2018-12-27 2020-11-01 國立大學法人京都大學 Ｔ細胞受體的變體
WO2020150391A1 (en) * 2019-01-15 2020-07-23 Falcon Therapeutics, Inc. Engineered stem cell constructs and uses thereof
CN113382768A (zh) 2019-02-01 2021-09-10 国立大学法人京都大学 细胞的检测方法
KR20210144793A (ko) 2019-03-29 2021-11-30 고리츠다이가쿠호진 요코하마시리츠다이가쿠 스크리닝 방법 및 독성 평가 방법
TW202104590A (zh) 2019-04-10 2021-02-01 國立大學法人京都大學 類生體組織結構體的製造方法
EP3969571A4 (en) 2019-05-14 2023-05-24 Aleph Farms Ltd. AGGREGATES OF PLURIPOTENT CELLS AND THEIR USE
TW202113062A (zh) 2019-06-11 2021-04-01 國立大學法人京都大學 腎間質細胞的製造方法
WO2021003462A1 (en) 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP4019549B1 (en) 2019-08-20 2025-06-04 Orizuru Therapeutics, Inc. Method for enriching cardiac myocytes
JP7709737B2 (ja) 2019-10-21 2025-07-17 オリヅルセラピューティクス株式会社 増殖抑制剤
US20220411752A1 (en) 2019-11-01 2022-12-29 Kyoto University Method for producing t cells
AR120538A1 (es) 2019-11-25 2022-02-23 Univ Kyoto Banco de células maestras de células t
EP4123016A4 (en) 2020-03-19 2024-06-19 Orizuru Therapeutics, Inc. Method for purifying cardiomyocytes
AU2021239654A1 (en) 2020-03-19 2022-10-27 Orizuru Therapeutics, Inc. Cardiomyocyte purification method
US20230159891A1 (en) 2020-03-31 2023-05-25 Kyoto University T cell progenitor production method
JPWO2021241668A1 (enExample) 2020-05-28 2021-12-02
CN112201307B (zh) * 2020-09-23 2024-09-17 温州医科大学 一种转录本注释方法以及筛选长非编码rna和内源逆转录病毒来源长非编码rna的方法
US20230399607A1 (en) 2020-11-20 2023-12-14 Orizuru Therapeutics, Inc. Maturation agent
US20240318141A1 (en) 2021-02-09 2024-09-26 Orizuru Therapeutics, Inc. Maturation agent
EP4306633A4 (en) 2021-03-09 2025-03-19 National University Corporation Tokyo Medical and Dental University METHOD FOR PRODUCING CELL CLUSTERS
KR20230167063A (ko) 2021-04-08 2023-12-07 다케다 야쿠힌 고교 가부시키가이샤 T-세포 활성화 방법
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
EP4332215A4 (en) 2021-04-28 2025-05-14 National University Corporation Tokyo Medical and Dental University Method for producing cells
CN113278686A (zh) * 2021-06-11 2021-08-20 扬州大学 一种研究dna甲基化调控重编程过程的方法
EP4410965A4 (en) 2021-09-27 2025-09-24 Univ Kyoto T LYMPHOCYTE PRODUCTION PROCESS
US20250195655A1 (en) 2022-02-04 2025-06-19 Kyoto University T cell production method
EP4497822A1 (en) 2022-03-23 2025-01-29 Kyoto University Method for producing regulatory t cells
CA3253987A1 (en) 2022-04-25 2025-07-04 Orizuru Therapeutics Inc MATURATION AGENT EXHIBITING BOTH ALK5 INHIBITORY AND CDK8/19 INHIBITORY ACTIVITY
WO2023243627A1 (ja) 2022-06-17 2023-12-21 国立大学法人京都大学 胸腺上皮細胞の製造方法
EP4556555A1 (en) 2022-07-14 2025-05-21 Orizuru Therapeutics, Inc. Fibrin gel sheet for cell transplantation
EP4563697A4 (en) 2022-07-25 2025-11-12 Univ Kyoto IN VITRO CULTURE METHOD FOR INDUCING OVARIAN FOLLICLES FROM PRIMATE FETAL OVARIAN CELLS
JPWO2024024551A1 (enExample) 2022-07-26 2024-02-01
WO2024029617A1 (ja) 2022-08-05 2024-02-08 国立大学法人京都大学 心筋の製造方法
EP4570902A1 (en) 2022-08-08 2025-06-18 Healios K.K. Method for producing cell aggregates
WO2024050517A1 (en) * 2022-09-02 2024-03-07 The University Of North Carolina At Chapel Hill Methods of making and using anticancer reprogrammed b cells
TW202421780A (zh) 2022-09-26 2024-06-01 國立大學法人京都大學 T細胞的製造方法
CN119948151A (zh) 2022-09-26 2025-05-06 国立大学法人京都大学 胰腺内胚层细胞的制造方法
JPWO2024071280A1 (enExample) 2022-09-29 2024-04-04
JPWO2024106444A1 (enExample) 2022-11-16 2024-05-23
WO2025038494A1 (en) 2023-08-11 2025-02-20 Tune Therapeutics, Inc. Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
WO2025059073A1 (en) 2023-09-11 2025-03-20 Tune Therapeutics, Inc. Epigenetic editing methods and systems for differentiating stem cells
WO2025106897A1 (en) * 2023-11-16 2025-05-22 Colossal Biosciences Inc. Methods and compositions for creating induced pluripotent stem cells

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US4846835A (en) 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5824837A (en) 1993-07-22 1998-10-20 Merck & Co., Inc. Expression of human interleukin-1β in a transgenic animal
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5698446A (en) 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9809178D0 (en) * 1998-04-29 1998-07-01 Univ Edinburgh Nuclear reprogramming of somatic cells
EP1129176A4 (en) 1998-11-09 2002-10-30 Es Cell Int Pte Ltd EMBRYONIC STEM CELLS
ES2338405T3 (es) * 1999-02-04 2010-05-07 Pluristem Ltd. Metodo y aparato para mantenimiento y expasion de celulas madre hemopoyeticas y/o celulas progenitoras.
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
WO2002064756A2 (en) 2001-02-15 2002-08-22 Whitehead Institute For Biomedical Research Stem cell identification
US20020137460A1 (en) * 2001-03-08 2002-09-26 Howard Sun Universal multi-band (5 bands and more) keyless RF remote control unit using bluetooth radio module as the base
JP4183614B2 (ja) 2001-05-31 2008-11-19 伸弥 山中 Ｅｓ細胞特異的発現遺伝子
JP2003033179A (ja) 2001-07-05 2003-02-04 Asahi Kasei Corp 可逆的遺伝子導入ベクター
US20050130144A1 (en) 2001-09-21 2005-06-16 Norio Nakatsuji Method of screening reprogramming factor, reprogramming factor screened by the method, method of using the reprogramming factor, method of differentiating undifferentiated fused cells and method of constructing cell, tissues and organs
DE10162080A1 (de) 2001-12-10 2003-06-26 Albrecht Mueller Verfahren zur Herstellung von Stammzellen mit erhöhtem Entwicklungspotential
GB0202149D0 (en) 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
GB0211904D0 (en) 2002-05-23 2002-07-03 Medical Res Council Nuclear transfer
WO2004009758A2 (en) 2002-07-23 2004-01-29 Nanodiagnostics, Inc. Embryonic stem cell markers and uses thereof
CA2530421C (en) * 2003-06-27 2015-04-21 Ethicon, Incorporated Repair and regeneration of ocular tissue using postpartum-derived cells
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US7964401B2 (en) 2004-02-19 2011-06-21 Kyoto University Screening method for somatic cell nuclear reprogramming substance affecting ECAT2 and ECAT3
EP1574499A1 (en) 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
JP4688793B2 (ja) 2004-03-23 2011-05-25 敏宏 赤池 多能性幹細胞の増殖方法
US20060148104A1 (en) 2004-10-29 2006-07-06 Massachusetts Institute Of Technology Detection of ion channel or receptor activity
US20100138947A1 (en) * 2005-04-29 2010-06-03 Ivan Vassiliev Method for Producing Stem Cells or Stel Cell-Like Cells from Mammalian Embryos
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
WO2007016566A2 (en) * 2005-08-01 2007-02-08 Nupotential, Llc Production of reprogrammed cells with restored potential
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
KR101420740B1 (ko) 2005-12-13 2014-07-17 교또 다이가꾸 핵초기화 인자
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
EP2038247A4 (en) 2006-06-27 2011-08-17 Jncasr Bangalore Site-specific inhibitors of histone metyltransferase [HMTASE] and method for their preparation
EP2137296A2 (en) * 2007-03-23 2009-12-30 Wisconsin Alumni Research Foundation Somatic cell reprogramming
CN105861443A (zh) 2007-04-07 2016-08-17 怀特黑德生物医学研究所 体细胞重编程
US20120282229A1 (en) * 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
EP3078738B1 (en) 2007-08-31 2020-05-20 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
US20110151447A1 (en) 2007-11-06 2011-06-23 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells
ES2690554T3 (es) 2008-03-17 2018-11-21 The Scripps Research Institute Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas
US20110061118A1 (en) 2008-03-17 2011-03-10 Helmholtz Zentrum Munchen Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
ES2722198T3 (es) 2008-05-02 2019-08-08 Univ Kyoto Método de reprogramación nuclear
CN105671065A (zh) 2008-06-13 2016-06-15 怀特黑德生物医学研究所 细胞编程和重编程
WO2010033920A2 (en) 2008-09-19 2010-03-25 Whitehead Institute For Biomedical Research Compositions and methods for enhancing cell reprogramming
CA2688804A1 (en) 2008-12-17 2010-06-17 The Uab Research Foundation Polycistronic vector for human induced pluripotent stem cell production

Also Published As

Publication number Publication date
JP2010523117A (ja) 2010-07-15
EP3878949A1 (en) 2021-09-15
US9382515B2 (en) 2016-07-05
US20170342386A1 (en) 2017-11-30
JP2020014479A (ja) 2020-01-30
RU2502799C2 (ru) 2013-12-27
AU2008236629B2 (en) 2014-03-06
US20190241874A1 (en) 2019-08-08
US20110076678A1 (en) 2011-03-31
CN101932705A (zh) 2010-12-29
MX348010B (es) 2017-05-23
JP2022031941A (ja) 2022-02-22
EP2145000A1 (en) 2010-01-20
JP2015051022A (ja) 2015-03-19
US9714414B2 (en) 2017-07-25
EP3878949B1 (en) 2025-06-04
CN105861443A (zh) 2016-08-17
US10093904B2 (en) 2018-10-09
JP2018086017A (ja) 2018-06-07
EP2145000A4 (en) 2010-05-05
JP2020014480A (ja) 2020-01-30
WO2008124133A1 (en) 2008-10-16
JP2024024049A (ja) 2024-02-21
JP6934501B2 (ja) 2021-09-15
MX352541B (es) 2017-11-29
CA2683056A1 (en) 2008-10-16
AU2008236629A1 (en) 2008-10-16
US20150118755A1 (en) 2015-04-30
RU2009140903A (ru) 2011-05-20
CA3071055A1 (en) 2008-10-16
EP2626416A2 (en) 2013-08-14
MX2009010847A (es) 2010-04-27
EP2626416A3 (en) 2013-12-18
JP2017035113A (ja) 2017-02-16
US20250188423A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
US20250188423A1 (en) Reprogramming of somatic cells
JP2017525347A (ja) ｉＰＳ細胞への再プログラミングの増強
JP2010528622A (ja) 体細胞から多能性細胞を生成する方法
AU2024203525A1 (en) Reprogramming of somatic cells
AU2020213357B2 (en) Reprogramming of somatic cells
EP2501803B1 (en) Methods of enhancing pluripotentcy
HK40058787A (en) Reprogramming of somatic cells
HK1227936A1 (en) Reprogramming of somatic cells
Boyer DNMT3b's Role in Hematopoietic Stem Cells

Legal Events

Date Code Title Description
EEER Examination request